StreetInsider.com News Articles

PharmaTher Launches M3DICINES(TM) National Network Program to Provide 3D-Printed Medicines for Rare Diseases, Discontinued Medicines, Drug Shortages and National Emergencies

Wed, 07 Oct 2026 08:00:00 -0400

The network is designed to bring together pharmacies, hospitals, contract manufacturers and government facilities to make personalized, rare disease, discontinued and short-supply medicines and emergency countermeasures, close to the patients who need them.

Toronto, Ontario--(Newsfile Corp. - October 7, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) (the "Company" or "PharmaTher"), a specialty pharmaceutical company advancing 3D-printed medicines, today announced the launch of the M3DICINES™ National Network Program (the "Network Program"). The program will build a national network of qualified sites that make personalized medicines on CraftMake™ pharmaceutical 3D printers, supported by PharmaTher's M3DICINES™ platform.

The network starts with U.S. 503A compounding pharmacies

PharmaTher Launches M3DICINES(TM) National Network Program to Provide 3D-Printed Medicines for Rare Diseases, Discontinued Medicines, Drug Shortages and National Emergencies

Wed, 07 Oct 2026 08:00:00 -0400

The network starts with U.S. 503A compounding pharmacies

PharmaTher Launches M3DICINES(TM) National Network Program to Provide 3D-Printed Medicines for Rare Diseases, Discontinued Medicines, Drug Shortages and National Emergencies

Wed, 07 Oct 2026 08:00:00 -0400

The network starts with U.S. 503A compounding pharmacies

PharmaTher Launches M3DICINES(TM) National Network Program to Provide 3D-Printed Medicines for Rare Diseases, Discontinued Medicines, Drug Shortages and National Emergencies

Wed, 07 Oct 2026 08:00:00 -0400

The network starts with U.S. 503A compounding pharmacies

PharmaTher Outlines Corporate Strategy and Upcoming Milestones; Launches New Corporate Website and Rebrands PERSONALIZ3D as M3DICINES

Mon, 05 Oct 2026 08:00:00 -0400

Highlights

M3DICINES™ 3D-printed medicines platform. One platform for PharmaTher's proprietary products, its network of CraftMake™ placements and partner services: CDMO, white-label products, formulation licensing and clinical trial supply.
Commercial launch of M3DICINES™. Initial orders of the CraftMake™ pharmaceutical 3D printer, the platform's entry point, are planned for Q4 2026.
Near-term products. First proprietary 503A peptide products are planned for Q4 2026, followed by a ketamine dissolvable tablet for telehealth in Q1 2027.
Rare pediatric NDA with voucher potential. Orphan drug and rare pediatric disease designation applications are planned for October 2026, with a pre-IND meeting in Q1 2027 and an NDA submission

PharmaTher Outlines Corporate Strategy and Upcoming Milestones; Launches New Corporate Website and Rebrands PERSONALIZ3D as M3DICINES

Mon, 05 Oct 2026 08:00:00 -0400

Highlights

M3DICINES™ 3D-printed medicines platform. One platform for PharmaTher's proprietary products, its network of CraftMake™ placements and partner services: CDMO, white-label products, formulation licensing and clinical trial supply.
Commercial launch of M3DICINES™. Initial orders of the CraftMake™ pharmaceutical 3D printer, the platform's entry point, are planned for Q4 2026.
Near-term products. First proprietary 503A peptide products are planned for Q4 2026, followed by a ketamine dissolvable tablet for telehealth in Q1 2027.
Rare pediatric NDA with voucher potential. Orphan drug and rare pediatric disease designation applications are planned for October 2026, with a pre-IND meeting in Q1 2027 and an NDA submission

PharmaTher Outlines Corporate Strategy and Upcoming Milestones; Launches New Corporate Website and Rebrands PERSONALIZ3D as M3DICINES

Mon, 05 Oct 2026 08:00:00 -0400

Highlights

M3DICINES™ 3D-printed medicines platform. One platform for PharmaTher's proprietary products, its network of CraftMake™ placements and partner services: CDMO, white-label products, formulation licensing and clinical trial supply.
Commercial launch of M3DICINES™. Initial orders of the CraftMake™ pharmaceutical 3D printer, the platform's entry point, are planned for Q4 2026.
Near-term products. First proprietary 503A peptide products are planned for Q4 2026, followed by a ketamine dissolvable tablet for telehealth in Q1 2027.
Rare pediatric NDA with voucher potential. Orphan drug and rare pediatric disease designation applications are planned for October 2026, with a pre-IND meeting in Q1 2027 and an NDA submission

PharmaTher Outlines Corporate Strategy and Upcoming Milestones; Launches New Corporate Website and Rebrands PERSONALIZ3D as M3DICINES

Mon, 05 Oct 2026 08:00:00 -0400

Highlights

M3DICINES™ 3D-printed medicines platform. One platform for PharmaTher's proprietary products, its network of CraftMake™ placements and partner services: CDMO, white-label products, formulation licensing and clinical trial supply.
Commercial launch of M3DICINES™. Initial orders of the CraftMake™ pharmaceutical 3D printer, the platform's entry point, are planned for Q4 2026.
Near-term products. First proprietary 503A peptide products are planned for Q4 2026, followed by a ketamine dissolvable tablet for telehealth in Q1 2027.
Rare pediatric NDA with voucher potential. Orphan drug and rare pediatric disease designation applications are planned for October 2026, with a pre-IND meeting in Q1 2027 and an NDA submission

PharmaTher Enters into Exclusive North American Distribution Agreement with Craft Health for CraftMake(TM) Pharmaceutical 3D Printing Platform

Thu, 01 Oct 2026 08:00:00 -0400

Agreement opens the U.S. and Canadian markets across all customer segments and lays the foundation for PharmaTher's personalized 503A products, FDA rare disease program, national emergency and medical countermeasures initiatives, and CDMO and white-label services

Highlights

PharmaTher is now the exclusive distributor in North America of Craft Health's CraftMake™ 3D printers, CraftControl™ software, CraftBlends™ printable formulations, consumables, and service.
Exclusivity covers every key customer segment: compounding pharmacies (503A and 503B), telehealth and digital health companies, CDMOs, hospitals, academic, research, and government institutions, and pharmaceutical, biotechnology, and healthcare companies.
PharmaTher estimates more than 10,000 potential placement sites in North America. Each placement is

PharmaTher Enters into Exclusive North American Distribution Agreement with Craft Health for CraftMake(TM) Pharmaceutical 3D Printing Platform

Thu, 01 Oct 2026 08:00:00 -0400

Highlights

PharmaTher is now the exclusive distributor in North America of Craft Health's CraftMake™ 3D printers, CraftControl™ software, CraftBlends™ printable formulations, consumables, and service.
Exclusivity covers every key customer segment: compounding pharmacies (503A and 503B), telehealth and digital health companies, CDMOs, hospitals, academic, research, and government institutions, and pharmaceutical, biotechnology, and healthcare companies.
PharmaTher estimates more than 10,000 potential placement sites in North America. Each placement is

PharmaTher Enters into Exclusive North American Distribution Agreement with Craft Health for CraftMake(TM) Pharmaceutical 3D Printing Platform

Thu, 01 Oct 2026 08:00:00 -0400

Highlights

PharmaTher is now the exclusive distributor in North America of Craft Health's CraftMake™ 3D printers, CraftControl™ software, CraftBlends™ printable formulations, consumables, and service.
Exclusivity covers every key customer segment: compounding pharmacies (503A and 503B), telehealth and digital health companies, CDMOs, hospitals, academic, research, and government institutions, and pharmaceutical, biotechnology, and healthcare companies.
PharmaTher estimates more than 10,000 potential placement sites in North America. Each placement is

PharmaTher Enters into Exclusive North American Distribution Agreement with Craft Health for CraftMake(TM) Pharmaceutical 3D Printing Platform

Thu, 01 Oct 2026 08:00:00 -0400

Highlights

PharmaTher is now the exclusive distributor in North America of Craft Health's CraftMake™ 3D printers, CraftControl™ software, CraftBlends™ printable formulations, consumables, and service.
Exclusivity covers every key customer segment: compounding pharmacies (503A and 503B), telehealth and digital health companies, CDMOs, hospitals, academic, research, and government institutions, and pharmaceutical, biotechnology, and healthcare companies.
PharmaTher estimates more than 10,000 potential placement sites in North America. Each placement is

PharmaTher Selects PD Labs, a National 503A Compounding Pharmacy, as the U.S. Center of Excellence for Its Personalized Medicine and Peptide Platform, PERSONALIZ3D(TM)

Tue, 18 Aug 2026 08:00:00 -0400

Marks the first milestone in PharmaTher's three-stage commercialization plan, advancing PERSONALIZ3D™ into early commercialization activities

Establishes the operating foundation to scale telehealth-enabled personalized medicines and pharmaceutical 3D printing, with the potential to generate recurring revenue across multiple channels

Toronto, Ontario--(Newsfile Corp. - August 18, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) (the "Company" or "PharmaTher"), a life sciences company focused on personalized medicines, today announced that PERSONALIZ3D™, the Company's integrated telehealth and pharmaceutical 3D printing platform for personalized medicines and peptides, is advancing toward commercialization through a collaboration agreement and the selection of Prescription Dispensing Laboratories, Inc. (PD

PharmaTher Selects PD Labs, a National 503A Compounding Pharmacy, as the U.S. Center of Excellence for Its Personalized Medicine and Peptide Platform, PERSONALIZ3D(TM)

Tue, 18 Aug 2026 08:00:00 -0400

PharmaTher Establishes PERSONALIZ3D(TM) to Commercialize a Personalized Medicine Platform Combining Telehealth and Pharmaceutical 3D Printing

Tue, 11 Aug 2026 08:00:00 -0400

Potential near-term commercialization through two synergistic business units: (i) a telehealth platform connecting patients with independent licensed healthcare providers and (ii) a North American network of pharmacy-based pharmaceutical 3D-printing systems for compounding medications, together forming a personalized medicine ecosystem

Toronto, Ontario--(Newsfile Corp. - August 11, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) (the "Company" or "PharmaTher"), a life sciences company focused on personalized medicines, today announced the establishment of PERSONALIZ3D™, an integrated ecosystem that will combine telehealth, pharmaceutical 3D printing, and pharmacy fulfillment to support the delivery of personalized medicines.

PERSONALIZ3D™ expands PharmaTher's previously announced Personaliz3D Peptides™ initiative into a

PharmaTher Establishes PERSONALIZ3D(TM) to Commercialize a Personalized Medicine Platform Combining Telehealth and Pharmaceutical 3D Printing

Tue, 11 Aug 2026 08:00:00 -0400

PERSONALIZ3D™ expands PharmaTher's previously announced Personaliz3D Peptides™ initiative into a

PharmaTher Collaborates with Craft Health to Evaluate CraftMake(TM) GMP-Ready Pharmaceutical 3D Printing Platform for Personalized Peptides

Wed, 29 Jul 2026 08:00:00 -0400

Toronto, Ontario--(Newsfile Corp. - July 29, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) ("PharmaTher" or the "Company"), a specialty pharmaceutical company focused on personalized medicines, announced today a collaboration with Craft Health Pte. Ltd. ("Craft Health") to evaluate Craft Health's CraftMake™ GMP-ready pharmaceutical 3D printing platform for PharmaTher's Personaliz3D Peptides™ partner ecosystem.

The collaboration will focus on developing novel peptide formulations and evaluating CraftMake™ as a reproducible platform for producing personalized peptide doses, combination formulations, controlled-release designs and differentiated dosage forms.

PharmaTher also intends to explore a broader commercial relationship with Craft Health that could support the deployment of

PharmaTher Collaborates with Craft Health to Evaluate CraftMake(TM) GMP-Ready Pharmaceutical 3D Printing Platform for Personalized Peptides

Wed, 29 Jul 2026 08:00:00 -0400

PharmaTher also intends to explore a broader commercial relationship with Craft Health that could support the deployment of

PharmaTher Launches Personaliz3D Peptides(TM) to Advance Personalized Peptide Care Following Positive FDA Advisory Committee Recommendations

Mon, 27 Jul 2026 08:00:00 -0400

New division will address the limitations of traditional peptide compounding through 3D printing and AI

PharmaTher plans to connect patients, physicians and qualified pharmacies through an integrated telemedicine platform

Positive PCAC recommendations represent an important potential step toward regulated access to compounded peptides in the United States

Toronto, Ontario--(Newsfile Corp. - July 27, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) ("PharmaTher" or the "Company"), a specialty pharmaceutical company focused on personalized medicines, announced today the launch of Personaliz3D Peptides™, a new division focused on developing and commercializing personalized peptide products and protocols using 3D printing and artificial intelligence technologies.

Patients and healthcare

PharmaTher Launches Personaliz3D Peptides(TM) to Advance Personalized Peptide Care Following Positive FDA Advisory Committee Recommendations

Mon, 27 Jul 2026 08:00:00 -0400

New division will address the limitations of traditional peptide compounding through 3D printing and AI

PharmaTher plans to connect patients, physicians and qualified pharmacies through an integrated telemedicine platform

Positive PCAC recommendations represent an important potential step toward regulated access to compounded peptides in the United States

Patients and healthcare

PharmaTher partners with KetaMist inventor to seek FDA approval

Tue, 21 Jul 2026 08:02:13 -0400

PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) announced a collaboration with Curtis W. Cassidy, M.D., the developer of KetaMist, a needle-free ketamine treatment platform, to pursue U.S. Food and Drug Administration approval for treatment-resistant depression and other neuropsychiatric conditions.

According to the company's press release, KetaMist has been used in more than 9,000 patient treatments to date. The platform is designed as a patient-controlled, needle-free delivery system intended to allow physicians to tailor ketamine dosing to individual patient response.

PharmaTher said it plans to apply regulatory and chemistry, manufacturing and controls experience from its prior FDA ketamine work to the KetaMist program.

PharmaTher Enters into Collaboration Agreement for KetaMist(R) to Advance Needle-Free Ketamine Treatment Toward FDA Approval

Tue, 21 Jul 2026 08:00:00 -0400

Collaboration combines more than 9,000 KetaMist® patient treatments with PharmaTher's prior FDA-approved ketamine experience

Pursuing an efficient FDA development pathway toward approval for treatment-resistant depression and other potential indications, leveraging KetaMist's real-world treatment foundation

KetaMist represents a differentiated, patient-controlled ketamine platform with the potential to build a multi-indication ketamine franchise

Toronto, Ontario--(Newsfile Corp. - July 21, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) ("PharmaTher" or the "Company"), a specialty pharmaceutical company focused on personalized medicines for peptides and psychedelics, today announced a collaboration with Curtis W. Cassidy, M.D., the inventor and developer of KetaMist® (ketamist.com), a needle-free ketamine treatment platform, to

PharmaTher Enters into Collaboration Agreement for KetaMist(R) to Advance Needle-Free Ketamine Treatment Toward FDA Approval

Tue, 21 Jul 2026 08:00:00 -0400

Collaboration combines more than 9,000 KetaMist® patient treatments with PharmaTher's prior FDA-approved ketamine experience

Pursuing an efficient FDA development pathway toward approval for treatment-resistant depression and other potential indications, leveraging KetaMist's real-world treatment foundation

KetaMist represents a differentiated, patient-controlled ketamine platform with the potential to build a multi-indication ketamine franchise

PharmaTher Updates Strategy on Personalized Medicines for Peptides and Psychedelics

Wed, 15 Jul 2026 08:00:00 -0400

Toronto, Ontario--(Newsfile Corp. - July 15, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) ("PharmaTher" or the "Company"), a specialty pharmaceutical company focused on personalized medicines, today provided a corporate update outlining its strategic focus on personalized medicines, specifically peptides and psychedelics.

PharmaTher believes peptides and psychedelics are gaining strong momentum and plans to capitalize on this opportunity using its MEDBOTX™ 3D-printing platform and AI-driven formulation tools. The Company's main focus is personalized medicines, aiming to develop treatments tailored to individual patient needs.

"Medicine is shifting toward treatments tailored to each patient," said Fabio Chianelli, Chairman and Chief Executive Officer of

PharmaTher Updates Strategy on Personalized Medicines for Peptides and Psychedelics

Wed, 15 Jul 2026 08:00:00 -0400

"Medicine is shifting toward treatments tailored to each patient," said Fabio Chianelli, Chairman and Chief Executive Officer of